SCHEMBL2661184

SCHEMBL2661184

COc1ccc(CN2Cc3nc4c(-c5cccc(OC)c5F)cccc4c(N)c3C2=O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.39
▸ LMNA P02545 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ PDE5A O76074 2/20 0.37
▸ IDH1 O75874 1/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ PDE10A Q9Y233 2/20 0.36
▸ CASP3 P42574 2/20 0.35
▸ APAF1 O14727 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ SENP8 Q96LD8 1/20 0.35
▸ SENP7 Q9BQF6 1/20 0.35
▸ SENP6 Q9GZR1 1/20 0.35
▸ CHRM5 P08912 1/20 0.35
▸ AURKA O14965 1/20 0.34
▸ HCRTR1 O43613 1/20 0.34
▸ HCRTR2 O43614 1/20 0.34
▸ NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2661670 0.92 KDM4E (0.39) KDM4ELMNAHTTNPSR1PDE5A
SCHEMBL2660724 0.91 MAPT (0.39) KDM4ELMNAHTTNPSR1PDE5A
SCHEMBL2661185 0.91 GABRG2 (0.39) KDM4ELMNAHTTNPSR1PDE5A
SCHEMBL2658694 0.91 GABRA1 (0.43) KDM4ELMNAHTTNPSR1PDE5A
SCHEMBL2661180 0.90 PDE5A (0.37) KDM4ELMNAHTTNPSR1PDE5A
SCHEMBL2661248 0.89 GABRG2 (0.45) KDM4EPDE5AMEN1KMT2ACHRM5
SCHEMBL2661222 0.89 CRHR1 (0.42) KDM4EPDE5AMEN1KMT2ACHRM5
SCHEMBL2656179 0.89 LMNA (0.39) KDM4ELMNAHTTNPSR1PDE5A
SCHEMBL2661041 0.88 LMNA (0.38) KDM4ELMNAHTTNPSR1PDE5A
SCHEMBL2661373 0.88 GABRG2 (0.43) KDM4ELMNAPDE5AIDH1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF KDM4E 2357/4885LMNA 1909/4885HTT 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback